Literature DB >> 17207021

Proteomics analysis in lung cancer: challenges and opportunities.

Takefumi Kikuchi1, David P Carbone.   

Abstract

Recent technological developments in proteomic analysis are bringing us new insights into the molecular classification of tumours. Although proteomic analysis in cancer profiling is still under development both in terms of the instruments used and the data analytical tools, this method has great potential advantages for the analysis of biospecimens of many types. Direct measurement of abnormally expressed or modified proteins in the tumour tissue and/or patient blood may be an effective approach for discovering new biomarkers. Proteomics has the significant advantage of being able to discern not only changes in expression levels but also in post-translational modifications. Thus, the proteomics approach to protein profiling and biomarker discovery uncovers biomarkers from a different viewpoint than microarray analysis. This review summarizes the range of proteomics technologies employed for cancer profiling, and how they have been used to derive new classification models for human lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17207021     DOI: 10.1111/j.1440-1843.2006.00957.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  11 in total

1.  Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.

Authors:  Meera Nanjundan; Lauren Averett Byers; Mark S Carey; Doris R Siwak; Maria Gabriela Raso; Lixia Diao; Jing Wang; Kevin R Coombes; Jack A Roth; Gordon B Mills; Ignacio I Wistuba; John D Minna; John V Heymach
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

2.  SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.

Authors:  Primo N Lara; James Moon; Paul J Hesketh; Mary W Redman; Stephen K Williamson; Wallace L Akerley; Fred R Hirsch; Philip C Mack; David R Gandara
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

3.  Characterizing tyrosine phosphorylation signaling in lung cancer using SH2 profiling.

Authors:  Kazuya Machida; Steven Eschrich; Jiannong Li; Yun Bai; John Koomen; Bruce J Mayer; Eric B Haura
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

Review 4.  Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis.

Authors:  Yue Yu; Jie He
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

5.  A simple two-gene prognostic model for adenocarcinoma of the lung.

Authors:  Carolyn E Reed; Amanda Graham; Rana S Hoda; Andras Khoor; Elizabeth Garrett-Mayer; Michael B Wallace; Michael Mitas
Journal:  J Thorac Cardiovasc Surg       Date:  2008-01-18       Impact factor: 5.209

6.  Lung cancer proteomics: recent advances in biomarker discovery.

Authors:  Paola Indovina; Eleonora Marcelli; Pasquale Maranta; Giulio Tarro
Journal:  Int J Proteomics       Date:  2011-09-15

7.  Gestational diabetes mellitus: a positive predictor of type 2 diabetes?

Authors:  Gregory E Rice; Sebastian E Illanes; Murray D Mitchell
Journal:  Int J Endocrinol       Date:  2012-05-23       Impact factor: 3.257

8.  Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients.

Authors:  Weiguo Han; Tao Wang; Andrew A Reilly; Steven M Keller; Simon D Spivack
Journal:  Respir Res       Date:  2009-09-25

Review 9.  Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening.

Authors:  Dean H Conrad; Jesse Goyette; Paul S Thomas
Journal:  J Gen Intern Med       Date:  2008-01       Impact factor: 5.128

10.  Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.

Authors:  Eun Young Kim; Ji Ye Jung; Arum Kim; Kwangsoo Kim; Yoon Soo Chang
Journal:  BMC Cancer       Date:  2017-07-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.